Gross margins were 63.8%, compared to 60.8% for Q1 'twenty four, an increase of three percentage points, primarily attributed to our test mix. Our operating loss for the quarter declined 31% to $4,600,000 compared to $6,600,000 for the first quarter of twenty twenty four, primarily driven by a growth in sales and gross profit, partially offset by a growth of 8% in operating expenses, which were primarily related to an increase in clinical studies, stock based compensation, and scale. Our net loss increased 8% to $9,200,000 compared to $8,500,000 for the prior year period, primarily driven by non cash fair value adjustments of $2,500,000 Excluding these non cash fair value adjustments, our net loss would have decreased 70% to $6,700,000 Finally, our fourth quarter adjusted EBITDA was negative $1,300,000 a 71% improvement over the first quarter twenty twenty four adjusted EBITDA of negative $4,500,000 We believe that we are on track to achieving our goal of positive adjusted EBITDA in the second quarter of this year. A reconciliation of IFRS to non IFRS financial measures has been provided in the tables included in this press release. Cash and cash equivalents as of 03/31/2025, were $65,700,000 Note that on April 29, we made our 2024 earnout payment to Exact Sciences in the amount of $28,000,000 After taking into account this earnout payment, our pro form a cash balance as of 03/31/2025 would have been $37,700,000 As a final comment, we have not seen, and we do not expect to see, a material impact on our financial operations from the recent developments related to tariffs.